DBV Technologies | DBVT - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amarin USD 18.97M 1.03M 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
DBV Technologies USD 3.63M 3.18M 2025-09
Esperion Therapeutics USD 39.42M 456K 2025-12
Galectin Therapeutics USD 1.48M 110K 2024-06
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Insmed USD 247.26M 34.78M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 156.6M 34M 2026-03